{{Rsnum
|rsid=3813928
|Gene=HTR2C
|Chromosome=X
|position=114583809
|Orientation=plus
|GMAF=0.1167
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=HTR2C
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 10.7 | 15.2 | 74.1
| HCB | 5.8 | 15.3 | 78.8
| JPT | 3.5 | 8.8 | 87.6
| YRI | 0.0 | 0.0 | 100.0
| ASW | 1.8 | 3.5 | 94.7
| CHB | 5.8 | 15.3 | 78.8
| CHD | 9.2 | 13.8 | 77.1
| GIH | 13.9 | 11.9 | 74.3
| LWK | 3.6 | 2.7 | 93.6
| MEX | 5.2 | 17.2 | 77.6
| MKK | 3.8 | 7.1 | 89.1
| TSI | 7.8 | 11.8 | 80.4
| HapMapRevision=28
}}[[rs3813928]] (-995G>A / G-995A) is a SNP upstream of [[HTR2C]].

{{PMID|19997080}} in a small sample of 45 autistic patients taking [[risperidone]] for up to one year,  HTR2A [[Rs6311]] (-1438G>A), DRD3 [[rs6280]] (Ser9Gly), HTR2C [[rs3813928]] (995G>A) and ABCB1 [[rs1128503)]] (1236C>T) were predictive of risperidone response

{{PMID Auto
|PMID=20504252
|Title=Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample
}}

{{PharmGKB
|RSID=rs3813928
|Name_s=HTR2C c.-995G>A, HTR2C:(-995)G>A
|Gene_s=HTR2C
|Feature=
|Evidence=PubMed ID:19997080
|Annotation=Risk or phenotype-associated allele: A Phenotype: Carriers of the A variant of HTR2C:(-995)G>A had higher Autism Treatment Evaluation Checklist (ATEC) scores, indicating worse symptoms and a poorer response to risperidone, than G homozygotes. Study size: 45 Study population/ethnicity: Children with Autism receiving risperidone Significance metric(s): p = 0.035 Type of association: PD
|Drugs=risperidone
|Drug Classes=
|Diseases=Autistic Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA165111371
}}

{{PMID|15717931|OA=1
}} Identification of functional SNPs in the 5-prime flanking sequences of human genes.

{{PMID|17016522}} The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study.

{{PMID|17632216}} The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3813928
|overall_frequency_n=9
|overall_frequency_d=92
|overall_frequency=0.0978261
|n_genomes=8
|n_genomes_annotated=0
|n_haplomes=12
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}